Law360, New York (November 23, 2009, 5:10 PM ET) -- The U.S. Food and Drug Administration has launched an expedited safety review of sibutramine based on a recent study showing that some patients taking the weight loss drug, which Abbott Laboratories markets as Meridia, have a higher rate of heart attacks, strokes and other cardiovascular events.
The agency is studying the initial data from a six-year study examining the effects of the drug on overweight or obese subjects at risk of a cardiovascular event, the FDA said Friday.
The regulator warned that it has not yet...
FDA Launches Safety Review Of Weight Loss Drug
To view the full article, take a free trial now.
